Asahi Kasei to Buy Swedish Drugmaker Calliditas for $1.1 Billion
17:18 JST, May 28, 2024
TOKYO (Reuters) – Japan’s Asahi Kasei said on Tuesday it offered to acquire Calliditas Therapeutics for about 11.8 billion Swedish crowns ($1.1 billion) as part of a plan to become a global drug company.
The Japanese firm will offer 208 crowns per share of Stockholm-based Calliditas and 416 crowns for each American depositary share in a deal approved by the boards of both companies, Asahi Kasei said in a statement.
The offer represents an 83% premium for Calliditas based on the closing price of 113.6 crowns on Monday.
Asahi Kasei, primarily known for its building materials business, said it wants to grow its healthcare segment globally in the fields of immunology, transplantation, and related diseases.
Calliditas focuses on orphan diseases and patients with unmet medical needs. In recommending that shareholders accept the tender offer, the Calliditas board said in a statement that the company stands to “realize the benefits of being part of a larger platform.”
$1 = 10.5681 Swedish crowns
"News Services" POPULAR ARTICLE
-
Harris Widens Lead over Trump to 47%-40%, Reuters/Ipsos Poll Finds
-
Hezbollah Leader Hassan Nasrallah was killed in Beirut Strike, Israel’s Military Says
-
Nippon Steel, US Steel Send Letter to Biden on Merger Plans
-
‘Shogun’ and ‘Hacks’ Win Top Series Emmy Awards
-
Foreigners Turn Net Sellers of Japanese Stocks for 2024 on Concerns Over Yen Strength
JN ACCESS RANKING
- Philippines Steps Up Defense of Northernmost Province with Eye on Possible Contingency Involving Taiwan
- Harris Widens Lead over Trump to 47%-40%, Reuters/Ipsos Poll Finds
- Typhoon Bebinca Could Approach Southern Japan In Days; Heavy Storms Expected from Saturday (Update 1)
- Mooncake Sales in China Frosty Ahead of Fall Holidays, as Sluggish Economy and Govt Rules Take Their Toll
- Japan-S. Korea Exchange Festival Held in Seoul